Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses
The Transmitter January 1, 2023 DOI: 10.53053/nbdr8957
Summary
A novel implant approach shows promise for managing severe seizures in Autism, with initial clinical trial data indicating a 60% reduction in seizure frequency across 85 participants. This biomedical innovation, rooted in physical medicine and rehabilitation, offers a potential reboot for neurological stability. Beyond implants, ongoing drug studies explore Psilocybin’s role in psychiatry, investigating its impact on neuroendocrine regulation and behavior. Such advancements in medicine raise important neuroethics questions regarding human enhancement, pushing the boundaries of psychology and treatment for autism.
Abstract
Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.